Cytokinetics, Incorporated (NASDAQ: CYTK) announced today top-line results from a Phase IIa clinical trial evaluating the safety of CK-1827452 in patients with ischemic cardiomyopathy and angina.  The primary safety endpoint was defined as stopping an exercise test during treatment with CK-1827452 (versus placebo) due to unacceptable angina at an earlier exercise stage than at baseline.

More: continued here

This entry was posted on Saturday, January 3rd, 2009 at 11:01 pm and is filed under Cardiovascular. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.